Miragen Therapeutics, a biopharmaceutical company focused on the discovery and development of therapies for cardiovascular and muscle disease based on microRNA biology has closed an $8M Series A financing co-led by Atlas Venture and Boulder Ventures. The Miragen scientific co-founders include successful academician serial entrepreneurs Eric Olson, Ph.D., Michael Bristow, M.D., Ph.D., and Marvin Caruthers, Ph.D.
This financing should enable the Company to define key microRNA’s, identify clinical indication(s) [perhaps post-myocardial infarction], ramp operations, complete large animal efficacy studies and generate a lead. Critical to the success of Miragen is the capacity to overcome bioavailability challenge of nucleic acid-based therapeutics; the Company may address said issue perhaps by the direct delivery of their miRNA’s to the heart.
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).